Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Top-3 GE Makers Report 10.4% Increase in Sales; Pace Down from Year Before
November 11, 2011
- Otsuka HD: Pharmaceutical Sales Up 1.7% in Apr-Sep Driven by Abilify
November 11, 2011
- President of Sawai Expects Generic Use Promotion in Next Medical Fee Revision
November 11, 2011
- Daiichi Sankyo Introduces AKT Inhibitor from US Firm, Obtains License Worldwide
November 11, 2011
- Ono to Restructure for Stronger Research Support System
November 11, 2011
- Sales of Ethical Drugs Up 5.6% in September: Crecon Report
November 11, 2011
- US FDA Accepts Filing for Astellas Pharma’s Mirabegron
November 11, 2011
- Nipro: Net Profits Down 81.5% due to Great East Japan Earthquake
November 11, 2011
- Fuso’s Ordinary and Net Losses were Pushed into Deficit by Quake (April-September 2011)
November 10, 2011
- Asahi Kasei Pharma to Accelerate Coagulant Development, Makes US Venture Wholly-Owned Subsidiary
November 10, 2011
- UCB, Otsuka to Apply for Domestic Approval of RA Drug in 2012
November 10, 2011
- Pharmaceutical Sales Up 0.5% in Bayer AG Jan-Sep Results
November 10, 2011
- Daiichi Sankyo Obtains Brazil Rights for OAB Treatment Uritos
November 10, 2011
- Nippon Shinyaku Increases Both Sales, Profits Driven by Growth of Vidaza
November 10, 2011
- Premium for New Drug Development Should Be Increased: Mr Miyoshi of IMS Japan
November 10, 2011
- Sanofi Expected to Overtake Pfizer as World’s Top Drug Maker in 2012: Evaluate Pharma
November 10, 2011
- Seikagaku to Conduct Add’l PIII Trial for Lumbar Disc Herniation Treatment SI-6603
November 10, 2011
- Toho HD’s Sales Increased to ¥2 Bil. in 1st-Half Driven by Dispensing Pharmacy Business
November 9, 2011
- Toho Holdings' Matsutani Says His Company Will Protect Its Own Prices
November 9, 2011
- Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September
November 9, 2011
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…